Sapio Sciences, the science-aware lab informatics platform, has partnered with Ultima Genomics to make multi-omics workflows more accessible and streamlined for researchers by integrating Sapio's AI-powered lab informatics solutions with Ultima's sequencing platform.

Through the partnership, the companies are hoping to provide efficient, traceable, and unified workflows for multi-omics research and clinical genomics.

Ultima Genomics' ultra-high throughput sequencing architecture is designed to reduce sequencing costs and scale beyond conventional technologies. Its multiomics sequencing capabilities enable researchers to examine layers of biology beyond DNA sequences; many changes linked to disease occur first in other omic layers, such as in the epigenome, with cancer.

Deeper levels of analysis are crucial for understanding complex biology, but have traditionally required multiple assays and fragmented workflows. This integration will enable researchers and clinicians to combine Ultima's data generation capabilities with Sapio's analytics, automation, and data management tools for an end-to-end solution.

Gilad Almogy, CEO and founder of Ultima Genomics, commented, "Partnering with Sapio Sciences aligns with our goals to enable leading sequencing labs and make genomic information more scalable. By integrating our high-throughput, low-cost sequencing platform with Sapio's AI-powered lab informatics platform, we're enabling a seamless, scalable solution for multi-omics research and clinical genomics. We're excited to empower organisations to accelerate discovery, drive AI-powered insights, and bring high-quality genomics into everyday workflows with unmatched efficiency and traceability."

Key Benefits

Andrew Wyatt, chief growth officer at Sapio Sciences, said, "This partnership gives Ultima's customers a direct path to combining world-class sequencing with equally powerful informatics. By removing workflow complexity, we're making it easier for labs to manage multi-omics data, gain insights faster, and scale without compromising quality or compliance."